The staff review argued against listing
FDA staff’s written review for the July 2026 meeting proposed keeping MOTS-c off the allowed-ingredient list for regular pharmacies.
The staff said they did not have enough information about the ingredient’s physical and chemical makeup. They also lacked studies showing its safety and effects in people.
As of September 30, 2026, that staff recommendation was a proposal rather than a final FDA decision.
The panel discussion was a separate step
The FDA advisory panel’s agenda placed MOTS-c in the evening session on July 23, 2026.
As of September 30, 2026, the FDA meeting page had no minutes or official record of the panel’s votes.
Written proposal
FDA staff’s memo is dated May 11, 2026.
Public meeting
MOTS-c was on the July 23, 2026, agenda.
Vote record missing
No official FDA vote record was posted as of September 30, 2026.
Advice is not a change in the rule
Under FDA’s rules as of September 26, 2026, the panel gives advice. The vote does not alter the list of ingredients that pharmacies are allowed to use.
To add an ingredient, FDA must publish a proposed rule, let the public comment and then make a final rule.
Read headlines with that distinction in mind
Ask which document supports a claimed change. A meeting agenda shows what was set for discussion. A staff paper shows staff’s position. Neither can stand in for a final rule.
Ask for the final document that changes the ingredient list. A claim about a meeting leaves that access question unanswered.
Keep this in mind
As of September 30, 2026, there was a staff proposal against MOTS-c listing and no published FDA record of the committee’s votes.
A question to take
Is this claim about a staff proposal, an official vote record or a final rule?
Open my notes